Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.
Eindhoven University of Technology, Dept. of Biomedical NMR, Eindhoven, The Netherlands.
Biomaterials. 2016 Mar;82:138-50. doi: 10.1016/j.biomaterials.2015.12.023. Epub 2015 Dec 22.
In numerous studies, thermosensitive liposomes (TSLs) for local heat-triggered delivery of Doxorubicin (Dox) to tumors have been investigated, with TSLs having different lipid formulations, drug loading methodology and testing procedures. To gain more insight in these parameters, we investigated TSLs with four variable DSPC-DPPC lipid ratios (50, 60, 70 or 80% DPPC and 5 mol% of DSPE-PEG2000) using either ammonium sulfate or a citrate buffer for Dox loading. Ammonium sulfate loading of Dox yielded more stable TSLs than citrate loading. At 37 °C, leakage was unnoticeable for all ammonium sulfate TSLs. At 42 °C, complete release occurred within seconds, except for 50% DPPC TSLs, where slow and incomplete release was observed in vitro but also in vivo using a dorsal skinfold window chamber. In contrast to in vitro assays, blood kinetics studies indicated a burst release of Dox upon injection and higher leakage for all TSLs. In therapeutic studies, hyperthermia in combination with TSLs repressed BFS-1 sarcoma growth. Our study shows that prediction of therapeutic efficacy purely based on differences found in vitro is difficult, instead, parameters obtained from pharmacokinetic studies in vivo, and the exact timing of the delivery protocol need to be taken into account.
在众多研究中,已经研究了热敏脂质体(TSL)用于局部热触发递送至肿瘤的阿霉素(Dox),其中 TSL 具有不同的脂质配方、药物加载方法和测试程序。为了更深入地了解这些参数,我们使用四种不同的 DSPC-DPPC 脂质比例(50%、60%、70%或 80%DPPC 和 5 mol%的 DSPE-PEG2000)的 TSL 进行了研究,分别使用硫酸铵或柠檬酸缓冲液进行 Dox 加载。与柠檬酸加载相比,硫酸铵加载的 Dox 产生更稳定的 TSL。在 37°C 下,所有硫酸铵 TSL 的泄漏都不明显。在 42°C 下,除了 50% DPPC TSL 外,所有 TSL 都在几秒钟内完全释放,在体外和体内(使用背部皮肤窗室)均观察到缓慢和不完全释放。与体外测定相反,血液动力学研究表明,注射后 Dox 会发生爆发释放,并且所有 TSL 的泄漏率更高。在治疗研究中,高热联合 TSL 抑制了 BFS-1 肉瘤的生长。我们的研究表明,纯粹基于体外差异预测治疗效果是困难的,相反,需要考虑体内药代动力学研究中获得的参数以及输送方案的确切时间。
J Control Release. 2016-6-28
Cancers (Basel). 2023-1-7
Pharmaceutics. 2022-10-11
Evid Based Complement Alternat Med. 2022-8-9
Pharmaceutics. 2021-8-27
Cancers (Basel). 2021-9-15